Humulin M3 (Insulin Human (Rdna))

Humulin M3 is indicated for the long‑term control of blood glucose in patients with diabetes mellitus.

• Adults with type 1 diabetes requiring basal insulin supplementation.
• Adults with type 2 diabetes inadequately controlled on oral agents or other insulin regimens.
• Pregnant women with pre‑existing diabetes when basal insulin is clinically appropriate (Category B).
• Patients transitioning from other basal insulin formulations to a recombinant human insulin.
• Use as part of a structured insulin therapy plan combined with mealtime rapid‑acting insulin.

• Humulin M3 contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation of the insulin receptor substrate, stimulating the phosphatidylinositol‑3‑kinase (PI3‑K) pathway and promoting translocation of GLUT‑4 transporters to the cell surface. This enhances glucose uptake in peripheral tissues and suppresses hepatic gluconeogenesis, thereby lowering circulating blood glucose levels in patients significantly.

Like other basal insulins, Humulin M3 may be associated with adverse reactions that vary in frequency and severity.

Common

• Hypoglycemia, especially if meals are missed or dosing is excessive.
• Injection‑site reactions such as redness, swelling, or bruising.
• Lipodystrophy, including lipohypertrophy at repeated injection sites.
• Weight gain associated with improved glycemic control.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or heart failure exacerbation in susceptible individuals.

Healthcare providers should consider several precautions before initiating Humulin M3 therapy.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Monitor blood glucose closely during periods of illness, stress, or changes in diet.
• Adjust dose in pregnant or lactating women, keeping pregnancy category B in mind.
• Avoid use in patients with known hypersensitivity to recombinant human insulin or any excipients.
• Educate patients on proper injection technique to reduce lipodystrophy risk.
• Consider cardiovascular status, as rapid glucose shifts can affect heart function.
• Store the product refrigerated and discard after the indicated in‑use period.

Humulin M3 can interact with other medicines, affecting glucose control or insulin action.

Avoid

• Concurrent use of other basal insulins or high‑dose insulin analogues without dose adjustment.
• Beta‑blockers that may mask hypoglycemia symptoms.
• Corticosteroids, which can increase insulin resistance and raise glucose levels.
• Thiazide diuretics that may potentiate hypoglycemia.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) – monitor for additive hypoglycemia.
• ACE inhibitors or ARBs – may enhance insulin sensitivity.
• Alcohol consumption – can cause delayed hypoglycemia.
• Exercise – increased glucose uptake may require dose reduction.